Biotechnology
Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability
SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress. Dr. Jay Mei, Antengene's...
2026-03-20 17:14
8380
Tescan Opens New Demo Lab in Korea to Support Semiconductor Failure Analysis, Reliability, and Academic Research Across Asia-Pacific
Integrated demo lab and office site brings demonstrations, training, and workflow support closer to semiconductor and academic users across APAC. SEOUL, South Korea, March 20, 2026 /PRNewswire/ -- Tescan today announced the official opening of its upgraded Tescan Korea Demo Lab & Office in Seoul,...
2026-03-20 16:00
4624
Ribo expands beyond the liver with RiboPepSTAR™ - enabling targeted siRNA delivery to multiple organs
SUZHOU, China and MÖLNDAL, Sweden, March 20, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) had been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleot...
2026-03-20 14:44
5659
MGI Tech and NUS Pharmacy and Pharmaceutical Sciences Announce Collaboration on DCS Lab to Accelerate Multi-Omics Innovation in Pharmaceutical Sciences
SINGAPORE, March 20, 2026 /PRNewswire/ -- MGI Tech Singapore Pte. Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, and the Department of Pharmacy and Pharmaceutical Sciences in the National University of Singapore's Faculty of Sci...
2026-03-20 11:17
6043
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Triple-Negative Breast Cancer of TROP2/HER3 Bispecific ADC JSKN016
SUZHOU, China, March 20, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of triple-negat...
2026-03-20 10:04
4242
D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
SHANGHAI, March 20, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (A...
2026-03-20 09:00
6431
Brii Biosciences Provides Corporate Updates and Reports Full Year 2025 Financial Results
Advancing HBV Functional Cure Toward Key Phase 2b Data Readouts Increasing Discovery Efforts to Drive Long-term Value Creation Strong Cash Position Supporting Strategic Priorities Upcoming Conference Calls: English Session: March 20 at 8:30 p.m. HKT / 8:30 a.m. ET Chinese Session: March 20 at ...
2026-03-19 19:00
7234
Belief BioMed announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved in Macao, China
SHANGHAI, March 19, 2026 /PRNewswire/ -- Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special Administrative Region of China for the treatment of adult patie...
2026-03-19 18:27
4712
Kelun-Biotech to Present the Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) from the OptiTROP-Lung03 Study
CHENGDU, China, March 18, 2026 /PRNewswire/ -- The 2026 European Lung Cancer Congress (ELCC) will be held in Copenhagen, Denmark, from March 25 to 28, 2026 (local time). At this congress, the final OS analysis from the pivotal study (OptiTROP-Lung03) of sacituzumab tirumotecan (sac-TMT, also know...
2026-03-18 22:31
8581
Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer
SUZHOU, China, March 18, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced the appointment of Mr. Fei Wang as Chief Financial Officer (CFO). Mr. Wang will be responsible for the company's capital operations, investment and financing management and investor relations, an...
2026-03-18 21:43
5728
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics
* The Atlas will expand known evolutionary genetic diversity by 100x, collecting novel genomic data from over 100 million new species across thousands of sites globally. * By partnering with Anthropic, Ultima Genomics, and PacBio, and powered by NVIDIA AI infrastructure, Basecamp Research aim...
2026-03-18 17:00
3595
Everest Medicines Enters into Letter of Intent with Hasten Biopharmaceuticals (Asia) Limited
SHANGHAI, March 18, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into a letter of...
2026-03-18 11:07
9640
Antengene to Present on Three Preclinical Programs at AACR 2026, Highlighting Next-Generation ADCs and AnTenGager™ TCEs
SHANGHAI and HONG KONG, March 18, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune ...
2026-03-18 08:30
5776
Innorna Announces FDA Clearance of IND for IN026, Advancing mRNA-based Therapies into Chronic Metabolic Diseases
IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's proprietary mRNA–LNP platform. HONG KONG SAR, China and SHENZHEN, China and CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Innorna, a clinical‑st...
2026-03-17 21:30
3508
Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therap...
2026-03-17 20:00
6744
/C O R R E C T I O N -- Gesynta Pharma/
In the news release, First patient dosed in Gesynta Pharma's endometriosis trial of vipoglanstat, issued 11-Mar-2026 by Gesynta Pharma over PR Newswire, the source was erroneously mentioned as Getinge Group rather than as Gesynta Pharma as incorrectly transmitted by PR Newswire. The complete, cor...
2026-03-17 17:24
7745
Ribo to present ex-hepatic delivery data at RNA Leaders Europe Conference
SUZHOU, China and MÖLNDALS, Sweden, March 17, 2026 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. ("Ribo" or "the Company", Hong Kong Stock Exchange code: 6938) has been invited to give a speech at the RNA Leaders Europe Conference in Vienna, Austria on March 19th, one of the top oligonucleo...
2026-03-17 11:00
6055
Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of PD-L1/VEGFR2 Bispecific ADC JSKN027
SUZHOU, China, March 17, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101) of JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) tar...
2026-03-17 10:32
6220
BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium
PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd
2026-03-17 09:05
4710
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Group Performance * Revenue: US$959.5 million, +61.4% year-on-year * Gross profit: US$553.2 million, +103.3% year-on-year * Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance * GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ...
2026-03-16 18:54
6256
Week's Top Stories
Most Reposted
Digital Identity Co. Modernizes Thailand Immigration Bureau Services with AWS
[Picked up by 314 media titles]
2026-05-28 15:06The Philippines Sets a New Standard in Muslim-Friendly Tourism
[Picked up by 290 media titles]
2026-05-26 10:30
Asian Society of Cardiovascular Imaging and Philips sign MOU to strengthen imaging capabilities across Asia Pacific
[Picked up by 289 media titles]
2026-05-28 17:34
ASEAN Business Advisory Council (ASEAN-BAC) and AVPN Establish Regional Platform to Strengthen Corporate Social Investment and Cross-Sector Collaboration Across Southeast Asia
[Picked up by 288 media titles]
2026-05-28 10:06Agoda and Philippines Department of Tourism announce strategic partnership to promote and elevate tourism
[Picked up by 287 media titles]
2026-05-27 09:16
Most Read
/DISREGARD RELEASE: Yangzhou Home Ka Crafts Co., Ltd./
2026-05-29 09:19
6671
ISDN's IDI Dynamics debuts high-speed laser marker for semiconductor assembly and test (OSAT)
2026-05-26 08:40
5716
NYSE Content Update: Mastercard Celebrates Two Decades as NYSE-Listed Company
2026-05-26 21:04
5670
